Healthy volunteers needed to unlock secrets of diabetes drug sitagliptin
NCT ID NCT06813014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how healthy people without diabetes respond to sitagliptin, an FDA-approved diabetes medication. Researchers want to understand why some people's bodies process sugar differently after taking the drug. About 400 healthy Amish adults will take part in two clinic visits, each lasting about 5 hours, where they will drink a sugary drink and have blood tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland Amish Research Clinic
Lancaster, Pennsylvania, 17602, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A simple card game could transform diabetes care
- Can a new injection help tackle obesity and diabetes? a safety trial begins